Drugs that contain Bimatoprost

1. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

CN104367580A ALLERGAN INC Form Ii Of 7 - (3, 5-Dihydroxy - -2-(3-Hydroxy - -5 - Phenyl - -1 - Alkenyl) - Cyclopentyl] - N-Ethyl - -5 - Enamide (Bimatoprost), Preparation Method And Use Method Thereof
Aug, 2017

(5 years ago)

CN102712584B ALLERGAN INC 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof
Nov, 2030

(8 years from now)

CN102712584A ALLERGAN INC 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants Apr, 2024

(1 year, 7 months from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants Feb, 2025

(2 years from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2027

(4 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2029

(6 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof Oct, 2034

(12 years from now)

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

2. Drug name - LATISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(10 months from now)

EP2802331B1 ALLERGAN Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists
Jan, 2033

(10 years from now)

EP2802331A1 ALLERGAN Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8986715 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists Jan, 2023

(3 months from now)

US8632760 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8263054 ALLERGAN Method of enhancing hair growth Jan, 2023

(3 months from now)

US8101161 ALLERGAN Method of enhancing hair growth May, 2024

(1 year, 7 months from now)

Treatment: Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.03% SOLUTION/DROPS;TOPICAL Prescription

3. Drug name - LUMIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

CN101137383B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN101137383A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

IN200706652P1 ALLERGAN Enhanced Bimatoprost Opthalmic Solution
Mar, 2026

(3 years from now)

IN263623B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B1 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434A2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

Treatment: A method of lowering intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.01% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.